Fiscal Year: January - December
Merck & Co., Inc. (MRK), listed on the NYSE, has a market capitalization of $298.76B. As of Apr 02, 2026, the stock is trading at $120.84 per share@else an unavailable price , offering investors a clear view of its current market value. Merck & Co., Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 16.6, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Merck & Co., Inc. also offers a dividend yield of 2.81%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Merck & Co., Inc. (MRK) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Merck & Co., Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Merck & Co., Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Merck & Co., Inc. is 24.17, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Merck & Co., Inc. (MRK) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Merck & Co., Inc. (MRK) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Merck & Co., Inc. (MRK) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Merck & Co., Inc.. To access the full SS Score, consider upgrading your subscription.
Merck & Co., Inc. is a significant player in the industry sector, with a market capitalization of $298.76B and a competitive P/E ratio of 16.6. Investors should compare these metrics with industry peers to gauge whether Merck & Co., Inc. is outperforming or underperforming within its sector.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30.
Verizon (VZ) is the only Dow stock in April 2026 meeting the ideal of annual dividends from $1K invested exceeding its share price, supported by robust free cash flow. Analyst forecasts suggest the to...
As Dow Jones slides into the “correction territory” and the benchmark S&P 500 index logs its fifth consecutive week of losses, investors are increasingly desperate for a port in the storm. According t...
Biotech firm Infinimmune said on Tuesday it has entered into a deal with Merck , that could be worth up to about $838 million in milestone payments, to discover and develop multiple antibodies for ...
ALAMEDA, Calif.--(BUSINESS WIRE)-- #AI--Infinimmune Enters Collaboration with Merck to Discover Novel Human Antibody Therapeutics.
Merck's oral drug reduced bad cholesterol by 64.6% in a late-stage trial, it said on Monday, as the company looks for its next blockbuster candidate.
RAHWAY, N.J.--(BUSINESS WIRE)--Enlicitide, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions Compared to Oral Non-Statin Therapies.
Merck & Co., Inc. (MRK) M&A Call Transcript
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Merck to spend $6.7 billion to buy Terns Pharmaceuticals, which is developing an oral treatment for leukemia.
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Merck said on Wednesday it would buy biotech Terns Pharma in a deal valued at up to $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming patent loss f...
The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection.
Terns' lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for certain patients with CML
Merck is nearing a roughly $6 billion all-cash deal to buy biotech firm Terns Pharma , the Financial Times reported on Tuesday, citing people familiar with the matter.
CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year res...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), today announced the...
Darmstadt, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- Employee volunteer program brings hands-on science learning to communities worldwide More than 600.000 students reached and nearly 200.000 employ...
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it will present new clinical and real-world data reaffirming the l...
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical data from the company's cardio-pulmonary pipeline wil...
Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly deliv...
CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing n...
Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Tempus AI Inc. (NASDAQ: TEM) on Tuesday inked a strategic collaboration agreement with Merck & Co. Inc. (NYSE: MRK) aimed at accelerating AI-driven precision medicine.
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 16.42B | -9.26% | Est @-9.3% |
| 2026 | 14.74B | -10.21% | Analyst x3 |
| 2027 | 23.68B | 60.61% | Analyst x4 |
| 2028 | 24.13B | 1.88% | Analyst x4 |
| 2029 | 23.28B | -3.52% | Analyst x3 |
| 2030 | 21.76B | -6.50% | Analyst x3 |
| 2031 | 21.61B | -0.73% | Est @-0.7% |
| 2032 | 21.66B | 0.26% | Est @0.3% |
| 2033 | 21.87B | 0.95% | Est @1.0% |
| 2034 | 22.16B | 1.34% | Est @1.3% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 9.14B | 1.00 | 9.14B |
| 2024A | 18.10B | 1.00 | 18.10B |
| 2025E | 16.42B | 1.08 | 15.27B |
| 2026E | 14.74B | 1.16 | 12.76B |
| 2027E | 23.68B | 1.24 | 19.06B |
| 2028E | 24.13B | 1.34 | 18.06B |
| 2029E | 23.28B | 1.44 | 16.21B |
| 2030E | 21.76B | 1.54 | 14.10B |
| 2031E | 21.61B | 1.66 | 13.02B |
| 2032E | 21.66B | 1.78 | 12.14B |
| 2033E | 21.87B | 1.92 | 11.40B |
| 2034E | 22.16B | 2.06 | 10.75B |
| Terminal | 453.69B | 2.06 | 219.99B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.
